If you are responsible for patient outcomes, operational performance, or the financial health of a hospital or hospital network, this page is written for you. Not for scientists. Not for engineers. For the people who have to make decisions about how their institution protects the people inside it — and answer for those decisions.
There is a meaningful difference between filtering air and purifying it. That distinction is not a marketing claim — it is a technical one, and it has direct consequences for patient outcomes, staff health, and the financial performance of your institution.
Filtration captures particles. The most advanced filtration systems available — HEPA, MERV 14, ULPA — were designed to trap airborne particles above a certain size threshold. HEPA filtration, which has become the default standard in clinical environments, was originally developed during the Manhattan Project to prevent radioactive particulate from re-entering the air scientists were breathing. It was not designed to inactivate biological pathogens. It was not designed to stop volatile organic compounds. It captures what it captures, and it leaves everything else in circulation.
Purification eliminates. A continuous air purification platform does not wait for pathogens to land on a filter. It actively inactivates biological and chemical contaminants before they reach the clinical environment — in a single pass, without byproducts, without recirculation of viable organisms, and without the downstream contamination risk that filtration systems carry when pathogens survive on and behind filters.
LifeAire’s patented multi-stage technology, deployed in the Aire~HCX hospital air purification system, combines molecular media filtration, UV pathogen kill, and VOC neutralization to achieve a 9-log reduction of infectious biological pathogens — meaning 99.9999999% of airborne pathogens are eliminated in a single pass. This performance level was validated against the anthrax spore, the most resistant biological organism used as a benchmark, confirming efficacy against all pathogens clinically relevant to hospital environments including MRSA, Clostridium difficile, influenza, tuberculosis, RSV, and SARS-CoV-2. For facilities where in-duct integration is not practical, the Aire~IRMU In-Room Modular Unit delivers the same multi-stage purification in a compact, plug-and-play format requiring no HVAC modification.
The distinction between filtration and purification is the foundation of everything that follows on this page.
Volatile organic compounds are a contamination category that HEPA filtration cannot address at all. VOCs are molecular-level chemical contaminants generated continuously by disinfectants, building materials, plastics, device components, and human occupancy. They pass straight through particle-based filters. In hospital environments, VOC burden contributes to respiratory distress in vulnerable patients — particularly in NICUs, oncology units, pulmonary clinics, and anywhere immunocompromised patients are present.
LifeAire’s Aire~VOC dedicated VOC neutralization unit addresses this specific contamination vector, and VOC remediation is built into every multi-stage LifeAire system as a core function rather than an add-on. Understanding your facility’s current VOC burden begins with an Aire~Analysis air quality assessment.
When hospital leaders evaluate air quality investments, the conversation typically centers on patients. That is the right starting point — but it is not the whole picture. Every person inside your facility is breathing the same air, and the case for a continuous infection control platform extends to all of them.
Every patient in a LifeAire-protected hospital environment is under less airborne biological and chemical stress. Their immune system is fighting less. Their body is recovering faster. That faster recovery has a direct financial expression: length of stay. A patient who goes home a day earlier frees a bed, reduces per-case cost, and improves the throughput of the entire unit.
Medical staff are in the protected environment more hours per day than any patient. A nurse working a twelve-hour shift in a unit with high airborne pathogen burden is breathing that air continuously. A 15-month peer-reviewed study documented a 47% reduction in staff call-outs in a LifeAire-protected facility — results available on the LifeAire research page. The operational and financial implications in overtime, agency staffing, and retention are significant and immediate.
The family member sitting at a patient’s bedside for six hours, the partner sleeping in a recovery room chair, the grandparent visiting the NICU — they are all breathing the same air as the patient. They are often already under emotional and physiological stress. They take what they breathe in that room home with them. A hospital that protects its visitors takes seriously its relationship with the community it serves.
Liability exposure, regulatory standing, quality scores, staff recruitment, and competitive positioning in a regional healthcare market are all downstream consequences of the air quality decisions made in the facilities planning process. A continuous infection control platform protects all four populations simultaneously, around the clock, every day the institution is operating.
LifeAire’s performance claims are not derived from laboratory bench testing or simulated environments. They are the product of IRB-approved, double-blind operational clinical studies conducted in full-capacity real-world healthcare settings. The results have been published in peer-reviewed journals including Surgery, the ASHRAE Transaction Journal, the Journal of Global Infectious Diseases, and Fertility and Sterility. The full library of published research is available at lifeaire.com/resources.
For hospital leaders evaluating any air purification claim, the distinction between operational clinical evidence and laboratory data is not a minor technical point. It is the difference between knowing what a system does in a controlled environment and knowing what it does in your environment — with real patients, real staff, real census variation, real seasonal pathogen load, and real operational complexity.
In long-term care and senior living environments, in IVF programs where the technology originated, and in life sciences and cell and gene therapy facilities through the Aire~LSX system, the same technology platform has produced consistently documented outcomes. LifeAire’s technology is protected by 23 patents — details at lifeaire.com/ip — and has received the Edison Award in consecutive years, recognized for innovation in healthcare environments. Full awards history at lifeaire.com/awards.
The most common entry point for the financial conversation about air purification is HAI reduction. It is a legitimate metric — HAIs cost U.S. hospitals $28.4 billion annually, and 43% of U.S. hospitals have been penalized for HAC and HAI rates. But leading with HAIs alone understates the financial case significantly.
Approximately 3% of hospital patients acquire a healthcare-associated infection. Of those HAIs, roughly 10% are attributable to airborne transmission — the specific vector that air purification addresses. That means the direct HAI benefit of a continuous air purification platform reaches approximately 0.3% of your total patient census through this single mechanism. That is a meaningful number when you calculate the per-case cost of an HAI, the associated CMS penalties, the readmission risk, and the malpractice exposure. But it is not the primary financial driver.
Length of stay is the primary financial driver.
Every patient in a LifeAire-protected environment is under less airborne biological stress. Their immune system is spending less energy fighting off ambient pathogens and more energy recovering from whatever brought them in. That physiological difference translates across the entire patient census, not just the 0.3% who would have acquired an airborne HAI.
At St. Luke’s Allentown, the combination of HAI reduction and LOS reduction produced $2.3 million in documented savings in a single year across 32 protected beds. The Aire~HCX system installed at that facility cost less than $125,000 fully installed. The hospital subsequently purchased 24 additional systems and rolled them out across the network. St. Luke’s University Health Network was ranked number one in the country for the lowest HAI rates in their system in the year following that expansion.
Even at a conservative 5% reduction in length of stay — far below the 39% documented at St. Luke’s — the system pays for itself within two years based on standard per-bed cost calculations. The financial case also includes staff absenteeism reduction, lower surface cleaning burden, fewer readmissions, reduced CMS penalty exposure, improved patient satisfaction scores, and the competitive positioning value of operating at a demonstrably higher environmental standard than peer institutions.
Across LifeAire’s installed base — which includes institutions such as Mayo Clinic, Stanford, Yale, Northwestern, Duke, and UCSF, all documented on the LifeAire Centers of Excellence page — there is a consistent pattern in the characteristics of the organizations that adopt and benefit most from continuous air purification.
They treat infection prevention as a strategic priority, not a regulatory requirement. In a regulatory frame, infection control is a checklist — you meet the standard, you check the box, you move on. In a strategic frame, infection control is a competitive and clinical differentiator. These institutions ask not whether they are compliant but whether they are leading.
They operate with interdisciplinary leadership. The decision to adopt a continuous air purification platform is not made by a single department. It requires collaboration between infection prevention, nursing leadership, facilities management, finance, and clinical leadership. Institutions where these functions operate in silos consistently struggle to evaluate and adopt solutions that sit at the intersection of infrastructure and patient care.
They empower their infection control leadership. In the best-performing institutions, the infection preventionist is a clinical strategist with real authority and real resources. When infection control leadership has both the authority to recommend change and the data literacy to make the case, institutions move faster and more decisively.
They understand value-based care. Institutions that have internalized the financial relationship between clinical outcomes and operational performance — where a CFO understands that a shorter length of stay means more throughput, better margins, and stronger payer relationships — are the institutions that see the air quality investment clearly. Read what LifeAire’s existing customers say at lifeaire.com/testimonials-about-lifeaire.
For hospital leaders conducting a formal evaluation of air purification solutions, the following criteria represent the minimum standard of rigor the decision deserves.
Review the leadership and scientific credentials of the team behind the technology at lifeaire.com/leadership.
LifeAire Systems is not an air filtration upgrade. It is a continuous infection control platform — operating 24 hours a day, seven days a week — that protects every person in the clinical environment simultaneously: patients recovering from procedures, medical staff working full shifts in the same air, and the family members and friends who sit at the bedside for hours.
The 0.3% of patients who might have acquired an airborne HAI are the most visible beneficiaries. But the faster recoveries, the shorter stays, the staff who came to work healthy, the visitor who did not bring something home — those are the patients, the people, and the outcomes that a hospital cannot easily count but cannot afford to ignore.
The evidence is peer-reviewed. The outcomes are documented. The guarantee is in writing.
